The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Open accessAbstract
Cancer therapy by entrapment: Mutations in the KRAS oncogene occur at high frequency in several of the most lethal human cancers, including lung and pancreatic cancer. Substantial effort has thus been directed toward developing KRAS inhibitors. KRAS encodes an enzyme that binds the nucleotide GTP and hydrolyzes it to GDP. It had been thought that oncogenic mutations disable this hydrolytic activity, locking KRAS in the GTP-bound, active state. Surprisingly, Lito et al. found that a certain KRAS mutant (G12C) retains hydrolytic activity and continues to cycle between its active and inactive states. They describe a compound that inhibits KRAS(G12C) signaling and tumor cell growth by binding to the GDPbound form of KRAS, trapping it in its inactive state. Science , this issue p. 604
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“early preclinical studies with KRASG12C inhibitors, such as ARS-1620, have suggested a potential role for adaptive feedback as a mechanism of resistance (7) (15).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“First, as described by Lito et al, increased RTK activity may lead to increased cycling of KRASG12C to its active GTP-bound form that hinders the binding of most KRASG12C inhibitors, which bind specifically to the inactive GDP-bound form (7).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“compounds have been identified that bind covalently to cysteine 12 within the switch II pocket of the GDP-bound form of the KRASG12C protein, preventing oncogenic signaling and causing potent tumor regressions in preclinical models.3-7”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the appreciable degree of nucleotide cycling observed in KRAS G12C -mutant protein proved critical for the development of clinically active KRAS G12C -selective inhibitors which bind the GDP-bound conformation and lock KRAS in the inactive state [7-9].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies have identified EGFR as a major mediator of adaptive feedback, and concomitant blockade of EGFR has been shown to enhance the antitumor activity of KRAS G12C inhibition12,15.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [15]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“The inhibitors function by locking KRASG12C in an inactive GDP bound state, exploiting the unique property of KRASG12C to cycle between the GDP- and GTP-bound states (6,7).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“These resistance mutations probably increase the fraction of KRAS protein in the active GTP-bound form that does not bind to the drug.4”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Preclinical studies have identified EGFR as a major mediator of adaptive feedback, and concomitant blockade of EGFR has been shown to enhance the antitumor activity of KRAS G12C inhibition12,15.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Given this particular feature of the KRAS G12C mutant protein, the efficacy of these compounds can be increased by concomitant receptor tyrosine kinase (RTK) inhibition that further maintain KRAS G12C in a GDP-bound conformation, facilitating the binding of the covalent inhibitor(7-9).”
From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“It is known that RTK inhibition in NSCLC preclinical models can potentiate KRAS G12C covalent inhibitors, by slowing down exchange factors favoring a GDP-bound status of KRAS(8).”
From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [8]
In the citing paper
“ARS-853 was firstly selected as a potent inhibitor that suppresses K-RasG12C-dependent cell proliferation.4,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“The binding of these compounds to K-RasG12C induces structurally disordered switch I/II, which converts the GTP preference of naive K-RasG12C to GDP.”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“However, it failed to demonstrate in vivo efficacy due to undesirable pharmacokinetics.4,5,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“Consequently, a large fraction of K-RasG12C protein is trapped in the inactive GDP-bound state, which impairs its interaction with downstream effectors, such as rapidly accelerated fibrosarcoma kinase (RAF).3,4,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“For example, secondary KRAS mutations would confer intrinsic resistance to ARS-853 in KRASG12C mutant models by either potentiating nucleotide exchange (secondary mutation: Y40A, N116H, or A146V) or impairing inherent GTPase activity (secondary mutation: A59G, Q61L, or Y64A) (Figure 3D).49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“Instead, K-RasG12C inhibitors act primarily through targeting MAPK/ERK pathway for growth inhibition.4, 5, 6, 7,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“These preclinical findings strongly imply that intrinsic resistance might be accountable for the heterogeneous responses to K-RasG12C inhibition in the clinic.4, 5, 6, 7,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“In most KRASG12C mutant models, the phosphorylation status of AKT and mTORC1-effector ribosomal protein S6 is barely affected by K-RasG12C inhibition.6,7,12,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“In line with the these findings, inconsistent results were observed co-treating KRASG12C mutant cancer cells with K-RasG12C inhibitors plus either MEK or ERK inhibitors, limiting the use of these drug combinations in the clinic.6,12,49”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“Lito et al.49 reported that the effect of ARS-853 was potentiated by EGFR inhibition in H2122 and Calu-1 cells.”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [49]
In the citing paper
“improvements in drug design have culminated in the development of inhibitors that are selective for mutant KRAS in its active or inactive state.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [65]
In the citing paper
“Accordingly, inhibitors of this type are KRASG12C specific; therefore, they do not affect RAS signalling in non-malignant cells65,70–72 and, at least theoretically, have a low risk of on-target, off-tumour toxicities.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [65]
In the citing paper
“KRASG12C is not permanently GTP-bound and maintains a dependency on upstream receptor tyrosine kinase (RTK) signaling for GEF-mediated GTP reloading (9, 10).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [9]
In the citing paper
“The rationale for pursuing SHP2 and SOS1 inhibitors as pan-KRAS inhibitors is grounded in the evidence that several (K)RAS oncoproteins, including KRASG12C, still cycle between an inactive and active state and rely on upstream activation and nucleotide exchange to exhibit their full transforming potential (9–13, 33, 34).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [9]
In the citing paper
“G12C-Is bind an evanescent pocket in KRAS-GDP, positioning a reactive group to couple to the mutant cysteine.”
From SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling (2021) · cites this paper as Lito et al., 2016
In the citing paper
“follow-up studies indicated that these initial compounds showed only limited potency (39, 40).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [39]
In the citing paper
“Binding of compound 12 to the switch II pocket impaired KRAS signalling by shifting nucleotide affinity from favouring GTP to GDP and led to the accumulation of KRAS in its inactive state91.”
From Advances in covalent drug discovery (2022) · cites this paper as [91]
In the citing paper
“Still, the mutant KRAS undergoes GDP–GTP cycling [5].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Niesen, F., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,420
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
GEFs and GAPs: Critical Elements in the Control of Small G Proteins
Bos, J. L., Rehmann, H., & Wittinghofer, A. (2007) · Cell · doi:10.1016/j.cell.2007.05.018 · Cited by 1,903
The Guanine Nucleotide-Binding Switch in Three Dimensions
Vetter, I. R., & Wittinghofer, A. (2001) · Science · doi:10.1126/science.1062023 · Cited by 1,875
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants
Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1128/MCB.8.6.2472 · DOI
Cited by
Sorted by citations
Items 601–700 of 700
García-Pardo, M., & Garrido, P. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-838 · Cited by 1
Targeting oncogenic K-Ras mutants with a small-molecule degrader through Nedd4-1Preprint
Zeng, T., Jiang, T., Zhang, B., Zhang, T., Dai, W., Yin, X., Li, Y., Wu, C., Wu, Y., Chi, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.26.591418 · Cited by 1
Davoudi, Z., Dexheimer, T. S., Coussens, N. P., Silvers, T. E., Morris, J., Takebe, N., Doroshow, J. H., & Teicher, B. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.17.623998 · Cited by 1
Targeted KRAS G12V degradation elicits efficient and durable lung adenocarcinoma regression in vivoPreprint
Martín, A. J. M., García-Pérez, I. M., José, S. S., Rojo, P., Riego‐Mejías, C., Teodósio, C., Barbosa, B. M. G., Sánchez, C., Folch-I-Casanovas, I., Caballol, A. O., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.13.627539 · Cited by 1
Meraz, I. M., Wu, S., Xu, Y., Gao, L., Feng, M., Ren, C., Song, R., Zhang, R., Wang, Q., Xi, Y., et al. (2025) · eLife · doi:10.7554/elife.106875 · Cited by 1
Brønsted-basic small molecules activate GTP hydrolysis in Ras Q61 mutantsPreprint
Wang, Y., Chen, S., Wu, Y., Cao, Y., Shi, Z., Norinskiy, M. A., Wang, C. D., Celik, H., & Zhang, Z. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.04.686643 · Cited by 1
Lee, A. A., Mokhtari, D. A., Egan, E. D., Blacklow, S. C., Herschlag, D., & Fordyce, P. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.30.715055 · Cited by 1
Parker, K., Ghorbanpoor, S., Malik, W., Highfield, L., Wang, J., Hensley, E., Kelley, G., Clark, S., Ranieri, M., Sahu, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.27.718135 · Cited by 1
Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance
Udagawa, H., Shibata, Y., Nilsson, M. B., Nishii, K., Robichaux, J. P., Galan-Cobo, A., He, J., Poteete, A., Qian, Y., Molkentine, D., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103991 · Cited by 1
Miura, G. I. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2054
Fortschritte bei der Ras‐Inhibition aus medizinisch‐chemischer Perspektive
Sautier, B., Nising, C. F., & Wortmann, L. (2016) · Angewandte Chemie · doi:10.1002/ange.201608270
Mitosis interference of K-Ras driven lung cancer cells by magnetic stimulation
Zhang, N., Wang, S., Zhang, C., & Wang, S. (2016) · Digest of the Fifth Biennial IEEE Conference on Electromagnetic Field Computation · doi:10.1109/cefc.2016.7816238
Blocking KRAS Signaling for the Treatment of Lung Cancer: Mission Possible?
Horio, Y. (2018) · Haigan · doi:10.2482/haigan.58.953
Rodrigues, F. S. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2018.tde-26112018-080111
The ERBB network facilitates KRAS-driven lung tumorigenesis
Neidler, S., Hedley, A., Kruspig, B., Monteverde, T., Hewit, K. D., Neiswandt, B., Rosenwald, A., Shanks, E. J., Dick, C. P. C., & Murphy, D. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)61337-0
Development of split luciferase complementation probes sensing KRAS/effector interaction
Miyamoto, K., Ishihara, K., & Sawa, M. (2019) · Translational and Regulatory Sciences · doi:10.33611/trs.1_40
Liu, Z. (2018) · ThinkTech (Texas Tech University)
RAS-Mutationen in der molekularen Tumorkonferenz
Schäfer, R. (2019) · Der Pathologe · doi:10.1007/s00292-019-00702-w
Modeling Covalent Protein-Ligand Interactions
Ward, R. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11519-3
Large-Scale Prediction of the ARS Family Inhibitors of the Oncogenic KRASG12C Mutant
Kulakova, A. M., Popinako, A. V., & Khrenova, M. G. (2020) · Lecture notes in computer science · doi:10.1007/978-3-030-41032-2_40
A Novel Strategy for Identifying Non-covalent KRas Inhibitors
Zhao, H., Sabio, M. L., Topiol, S., Huang, K., Tanaka, N., Chu, W., Gubler, U., & Tolias, P. P. (2020) · Medical Research Archives · doi:10.18103/mra.v8i6.2137
Ras and Ras Signaling as a Therapeutic Target in Cancer
Sliker, B. H., & Campbell, P. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00006-2
iRhom2 regulates ERBB signalling to promote KRAS-driven oncogenesisPreprint
Sieber, B., Lu, F., Stribbling, S. M., Grieve, A. G., Ryan, A. J., & Freeman, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.06.455383
After Decades, RAS Mutation has Finally Become a Therapeutic Target
Naim, N., Moukheiber, S., Jaber, K., & Kourié, H. R. (2021) · Personalized Medicine · doi:10.2217/pme-2021-0015
KRAS G12D can be targeted by potent salt-bridge forming inhibitorsPreprint
Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J. W., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.13.472365
A novel role for RASSF1A in the regulation of RAS activation.
Stewart, D. H. (2020) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3505
Ge, J., Yuan, M., Lin, J., Ren, J., Dou, G., Yang, L., Zhou, Y., Xie, H., Wang, X., & Zhong, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1391554/v1
Evaluation of K-Ras4B dimer interfaces and the role of Raf effectorsPreprint
Chatzigoulas, A., Andreadelis, I., Doerr, S., Lamprakis, C., Theodoropoulou, A., Manchester, J. I., Velez‐Vega, C., Duca, J. S., & Cournia, Z. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.04.510804
Oncogenèse pulmonaire et bases biologiques des traitements ciblés
Richard, N., Jean-Jacques, B., Cortot, A. B., & Levallet, G. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00096-9
Discovery of a ‘Grail-Shaped’ Drug: Ne-ratinib and the Downregulation of Mutant RAS
Dent, P., Poklepovic, A. S., & Booth, L. A. (2019) · EMJ Oncology · doi:10.33590/emjoncol/10314967
Jones, G. D., Caso, R., Tan, K. S., Mastrogiacomo, B., Sánchez-Vega, F., Liu, Y., Connolly, J. G., Murciano‐Goroff, Y. R., Bott, M. J., Adusumilli, P. S., et al. (2023) · doi:10.1158/1078-0432.c.6530886.v1
Self-citationMonaco, K., Delach, S. M., Yuan, J., Mishina, Y. M., Fordjour, P., Labrot, E., McKay, D., Guo, R., Higgins, S. E., Wang, H. Q., et al. (2023) · doi:10.1158/1078-0432.22480650
Suzuki, S., Yonesaka, K., Teramura, T., Takehara, T., Kato, R., Sakai, H., Haratani, K., Tanizaki, J., Kawakami, H., Hayashi, H., et al. (2023) · doi:10.1158/1078-0432.c.6530453
Monaco, K., Delach, S. M., Yuan, J., Mishina, Y. M., Fordjour, P., Labrot, E., McKay, D., Guo, R., Higgins, S., Wang, H. Q., et al. (2023) · doi:10.1158/1078-0432.c.6530499
Data from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
Hitchman, T. D., Bayshtok, G., Ceraudo, E., Moore, A. R., Lee, C., Jia, R., Wang, N., Pachai, M. R., Shoushtari, A. N., Francis, J. H., et al. (2023) · doi:10.1158/1078-0432.c.6530301
Data from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., de la Cruz, F. F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2023) · doi:10.1158/1078-0432.c.6529850.v1
Data from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
Hitchman, T. D., Bayshtok, G., Ceraudo, E., Moore, A. R., Lee, C., Jia, R., Wang, N., Pachai, M. R., Shoushtari, A. N., Francis, J. H., et al. (2023) · doi:10.1158/1078-0432.c.6530301.v1
Suzuki, S., Yonesaka, K., Teramura, T., Takehara, T., Kato, R., Sakai, H., Haratani, K., Tanizaki, J., Kawakami, H., Hayashi, H., et al. (2023) · doi:10.1158/1078-0432.c.6530453.v1
Data from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., de la Cruz, F. F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2023) · doi:10.1158/1078-0432.c.6529850
Treatment of KRAS Mutant Microsatellite Stabilized Advanced Colorectal Cancer
朱, 增. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1351137
Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araújo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M. D., Minuti, G., et al. (2023) · doi:10.1158/2159-8290.23310275
Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araújo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M. D., Minuti, G., et al. (2023) · doi:10.1158/2159-8290.23310275.v1
Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araújo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M. D., Minuti, G., et al. (2023) · doi:10.1158/2159-8290.23641387
Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araújo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M. D., Minuti, G., et al. (2023) · doi:10.1158/2159-8290.23641387.v1
Oncogenèse pulmonaire et bases biologiques des traitements ciblés
Blons, H., Mansuet‐Lupo, A., Garinet, S., Wislez, M., Mascaux, C., Levallet, G., & Leroy, K. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00124-6 · Cited by 1
LKB1 suppresses growth and promotes the internalization of EGFR through the PIKFYVE lipid kinasePreprint
Ferrarone, J. R., Thomas, J., Unni, A. M., Zheng, Y., Nagiec, M. J., Gardner, E. E., Mashadova, O., Li, K., Koundouros, N., Montalbano, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.19.563158
Additional file 2 of Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14175865
Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?
Healy, F. M., Turner, A. L., Marensi, V., & MacEwan, D. J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1441938
Deck, S. L., Xu, M., Stankus, M., Milano, S. K., & Cerione, R. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.27.639303
Meraz, I. M., Wu, S., Xu, Y., Gao, L., Feng, M., Ren, C., Song, R., Zhang, R., Wang, Q., Xi, Y., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.18.643954
Advances in Research on Drugs Targeting KRAS Mutation
夏, 雪. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1572092
Unveiling KRAS G12D inhibition: from molecular dynamics to therapeutic strategies
Omotara, B. S., Solanki, P. R., Manica, A. K., Ajala, C. F., Junaid, I. O., Anifowose, L. O., Adeniran, T. R., Nwachukwu, F., Farayola, R. O., Abdulrasaq, I. T., et al. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2563084 · Cited by 1
Structure-based design and synthesis of novel highly potent and selective KRASG12C inhibitors
Gao, K., Bao, L., Li, S., Zhang, C., Xu, L., & Zhu, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118321
Additional file 1 of Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells
Du, R., Sullivan, D. K., Azizian, N. G., Liu, Y., & Li, Y. (2021) · Figshare · doi:10.6084/m9.figshare.14175862
Yang, Q., To, K. K. W., Hu, G., Fu, K., Yang, C., Zhu, S., Pan, C., Wang, F., Kewang, L., & Fu, L. (2024) · Figshare · doi:10.6084/m9.figshare.26733367
Additional file 1 of KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner
Laurent, P.-A., Milić, M., Quevrin, C., Meziani, L., Liu, W., Morel, D., Signolle, N., Clémenson, C., Lévy, A., Mondini, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24472444
Varol, A. (2025) · Mugla Journal of Science and Technology · doi:10.22531/muglajsci.1826880
Combating colorectal lung metastases via systemic therapy and thermal ablation: RAS mutation impact
Fan, H., Xu, T., Zeng, Y., Hu, J., Ding, R., Li, X., Zhao, F., Fu, C., Cun, J., Li, A., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004089
Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors
Kanemura, H., Takehara, T., Maenishi, O., Tomida, S., Iwawaki, N., Kunimasa, K., Nakayama, T., Watanabe, S., Suzuki, S., Sakai, K., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0489
Kwok, G. W., Lo, J., & Fung, T. H. W. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70353
Marqueurs prédictifs de réponse aux inhibiteurs de BRAF dans le mélanome cutané métastatique
Funck-Brentano, E. (2016) · theses.fr (ABES) · doi:10.70675/73a2af67z6d03z483czb461zb0527aec1a30
From undruggable to actionable: advances in KRAS targeting in colorectal cancer
Chan, M., Shelke, M., Townsend, A. R., Roy, A. C., Broadbridge, V. T., Karapetis, C. S., & Price, T. J. (2026) · Academia oncology. · doi:10.20935/acadonco8216
MAPK pathway modulation and its implications in KRAS mutant lung adenocarcinoma
Román, S. D. H. (2023) · theses.fr (ABES) · doi:10.70675/8eaccae1ze96bz4279zb69fzaafa5e50c341
Efficacy and synergy of low-dose radiotherapy combined with anti-PD-L1 based immunotherapy
Laurent, P.-A. (2023) · theses.fr (ABES) · doi:10.70675/e7695737z26a3z4747zafafzb19e3e74372b
Unlocking drug sensitivity in KRAS
MingCong, L. I., YueSong, Z. H. O. U., Qiao, T. D., QingLin, B. A. I., & Li, C. (2026) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0279
Introduction to Polysaccharides in Cancer Therapy
Yendurı, S., & Prashant, K. N. (2026) · doi:10.1002/9781394345472.ch1
Weiss, G. J., Loftus, J. C., Mallery, D. W., & Tran, N. L. (2026) · Cancers · doi:10.3390/cancers18091367
Yu, H., Yang, Y., Li, X., Hu, X., Guo, J., Wu, H., Wang, J., Wang, K., Han, Z., Sun, X., et al. (2026) · Journal of Nuclear Medicine and Molecular Imaging · doi:10.65457/jnmmi-2026-0018
Chen, G., Ban, Q., Wang, Z., Su, Y., Fang, L., & Gou, S. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118693
Pagba, C. V., Dilsha, K. M., Ojha, R., Jakubec, J. L., Liang, X., Sianoya, A. C., Medina, P. M. B., Gilbertson, S. R., & Gorfe, A. A. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00129
Targeting ATF3-mediated asparagine biosynthesis reverses acquired resistance to KRASG12C inhibitors
Zhu, Y., Zhang, C., Li, M., Ai, L., Xu, F., Yu, Y., Yu, S., Xu, X., Liu, Q., Zhu, M., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03838-1
Valencia-Sama, I., Kee, L., Weiss, A., Hayes, M. N., Ohh, M., & Irwin, M. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.24.734371
Therapeutic inhibition of RAS in non-small cell lung cancer
Nichols, K. B., & Herzberg, B. O. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1817943
Biochemistry at scale: Seeing both the forest and the trees
Harry, S. A., Vasavda, C., Wahida, A., Stevens, R., Singh, H., Goldman, I. D., Chabner, B. A., & Bar‐Peled, L. (2026) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2026.05.005
Robb, R. N., Ackermann, S. E., Degan, S. E., Taylor, K. E., Yang, R. Y., Marler, A. Z., Calvert, V. S., Pierobon, M., Lyons, S. P., Barker, N. K., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0731 · Cited by 2
Yang, X., Tao, X., Qi, W., Luo, R., Lan, T., Xie, K., Cai, Y., Gao, F., Lv, Y., Liu, C., et al. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101718
Luo, D., Zheng, J., Du, X.-K., Xia, D., Zhang, M., & Liang, Z. T. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c01767
Zhou, X., Du, H., Yang, H., Hu, Y., Wang, C., Zhang, M., Ding, X., & Wang, P. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1879034 · Cited by 1
Jin, S., Zhang, Z., Liang, F., Yang, Y., Lü, A., & Liang, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-00981-5
Kim, D., Lee, J. H., & Kim, D.-S. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02283-1
A High-Throughput Assay to Identify Specific Nascent Chain InhibitorsPreprint
Fischer, P. D., & Hiller, S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.03.749102
Chemical Genetic Targeting of the LRRK2 GTPase DomainPreprint
Prorok, R., Zhu, L., Bowcut, V., Wu, H. X., Guiley, K. Z., Morstein, J., & Shokat, K. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.03.749217
Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer
Kreidi, J., Hoyek, C., Eslinger, C. R., & Bekaii-Saab, T. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2738708
Stańczak, M., & Niazi, S. K. (2026) · Pharmaceuticals · doi:10.3390/ph19101578
Review of 2025 approved small-molecule drugs by China NMPA: A new milestone
Hu, Y., He, F., He, C., Cao, C., Zhong, N., Yang, Z., & Li, Y. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.10.015
BindingDB (2019) · UC San Diego · doi:10.7270/q2f191zc
BindingDB Entry 50018208: Design, Synthesis, and Bioevaluation of Pyrido[2,3-
BindingDB (2024) · UC San Diego · doi:10.7270/q2dj5ktj
BindingDB Entry 50023438: Covalent-Allosteric Inhibitors: Do We Get the Best of Both Worlds?
BindingDB (2026) · UC San Diego · doi:10.7270/q2h136xb
BindingDB Entry 50010526: Identification of the Clinical Development Candidate
BindingDB (2021) · UC San Diego · doi:10.7270/q2g164c5
BindingDB (2026) · UC San Diego · doi:10.7270/q27p94b7
BindingDB Entry 50007608: Design and Discovery of
BindingDB (2021) · UC San Diego · doi:10.7270/q20g3pg4
BindingDB (2022) · UC San Diego · doi:10.7270/q2t1578s
Uncovering KRAS -mutant allele-specific biology and vulnerabilities in non-small cell lung cancer
d’Arienzo, P. D., McDaid, W. J., Tinsley, K. L., Chen, T., Gasson, E. J., Lindsay, C. R., & Malliri, A. (2026) · Biochemical Journal · doi:10.1042/bcj20250138
Metadata
- Authors
- Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Wellspring Biosciences (United States) (US)
- Corresponding author
- Lito, Piro
- Rosen, Neal
- Venue
- Science
- Published
- 2016-02-05
- Volume
- 351
- Issue
- 6273
- Pages
- 604-608
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4955282
- OpenAlex
- W2233032895
- Semantic Scholar
- e165d3c03cf60d1cdc247a235e53363d62727803
- Cited by
- 691
- References
- 38
- Citations by year
- 2026: 53 · 2025: 62 · 2024: 69 · 2023: 75 · 2022: 86 · 2021: 92 · 2020: 71 · 2019: 58 · 2018: 47 · 2017: 49 · 2016: 29
- FWCI
- 31.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (P01CA129243-06, K08CA191082-01A1)
- Memorial Sloan Kettering Cancer Center Experimental Therapeutics (SKI12103)
- LUNGevity Foundation Career Development Award
- V Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS G12C, GTPase activity, nucleotide exchange, KRAS-driven cancers, tyrosine kinase signaling, tumor cell growth inhibition
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Alleles, Antineoplastic Agents, Azetidines, Cysteine, Cytidine Diphosphate, Enzyme Inhibitors, Glycine, Guanosine Triphosphate, Humans, Lung Neoplasms, Mutation, Piperazines, Protein Conformation, Time Factors, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, HEK293 Cells, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
